Olfaction is frequently mentioned as a "neglected sense", although the olfactory system has several interesting and unique anatomical and physiological features. Olfactory involvement is present in several degenerative disorders, especially in Alzheimer's disease (AD). The peripheral and central parts of the olfactory system are damaged even in the early stages of AD, manifesting in profound olfactory deficits. Besides the early pathology, the olfactory system may be involved in the pathogenesis of AD by providing a route of entry for pathological agents still unknown. In contrast to this olfactory vector hypothesis, the olfactory system can be used to deliver therapeutic agents in AD, such as nerve growth factor and insulin, by decreasing the side-effects of the therapy or providing a non-invasive method of delivery.
Introduction
Alzheimer's disease (AD) is a devastating primary degenerative disorder of the nervous system. It is characterized neuropathologically by the accumulation of intraneuronal neurofibrillary tangles (NFT) and neuropil threads, together with extracellular senile plaques, and clinically by progressive cortical dementia with short term memory loss as an initial symptom. The pathomechanism of the disease is unknown and only modest symptomatic relief is provided by currently available treatments [1] .
Olfaction is frequently mentioned as a "neglected sense", although it has several interesting and unique anatomical ( Figure 1) and physiological features [2] . It is the only site of the central nervous system (CNS) where continuously replaced primary olfactory epithelial cells grow their axons into the CNS and form new functional synapses with the mitral cell processes in the olfactory bulb (OB) [3] . In addition, environmental factors such as toxins or pathogens can easily reach the CNS through the olfactory pathway. Moreover, the olfactory system is the main afferent of the limbic regions which are involved in memory formation and affected early in the course of AD pathology [4] . As shown by these peculiarities, the olfactory system has an exceptional role in AD. Neuropathological changes of the olfactory epithelium, bulb and cortical structures, olfactory dysfunction, and the role of the olfactory system in the pathogenesis of AD are summarized in this review, together with an outlook on the possible olfactory system-based therapeutic options.
Pathology of the olfactory epithelium
The olfactory epithelium in the postero-dorsal region of the nasal cavity contains primary olfactory receptor neurons (ORN) (about 6 million in every human nose) which send their axons through the cribriform plate into the OB [5] .
Hyperphosphorylated tau laments
were found in the ORN of AD patients [6] [7] [8] which raises the possibility of in vivo histological diagnosis from biopsied tissue [9] . Unfortunately, these promising results were not verified by subsequent studies. Tauimmunoreactive laments were detected even in non-demented young and aged adults [10] [11] [12] , or the pathology was detected only in advanced stages of AD and not in its mild or moderate stages [13] . Tau-containing dystrophic neurites were present not only in AD, but also in other neurodegenerative diseases, as well as in normal aging; only fetal and neonatal cases were found to not possess them [10] . Recently, the pathology of the olfactory epithelium was studied in detail by Arnold et al. [14] in a large number of neurites in the olfactory epithelium [15] . TDP-43-containing inclusions were not found. In spite of these non-specific findings, the authors again raised the suggestion of Tabaton et al. [9] to use the olfactory epithelium as a biomarker for AD. It should be mentioned that Crino et al.
[16] found a higher percentage of AD patients (10 out of 12) bearing β-amyloid depositions in the olfactory epithelium.
Besides β-amyloid and tau pathology, other morphological abnormalities of the olfactory epithelium were also shown in AD.
Apolipoprotein E (ApoE) was found in the Schwann cells of the olfactory nerve bundles and the number of ApoE-immunoreactive ORN was 3.5 times greater in AD than in controls with a similar number of ORN [17] . These features suggest that membrane transport processes might be altered in AD.
Increased activity of oxidative processes was also demonstrated in the olfactory epithelium.
Immunoreactivity of 3-nitrotyrosine was localized in ORN, while in controls immunoreactivity occurred in vascular endothelial cells only [18] . Increased oxidative stress in the olfactory epithelium in AD was also suggested by macrophage infiltration, which was absent in controls [18] . The role of oxidative stress was also supported by the increased superoxide dismutase immunoreactivity seen in AD compared to controls, especially near the surface and in the basal region of the epithelium [19] . Similarly, the immunoreactivity of metallothionein (which is induced by oxidative stress) was increased in AD [20] .
Oxidative damage in the olfactory epithelium was only partially similar to that seen in cortical regions in AD: nucleic acid or protein oxidation was not demonstrated in the olfactory system, while lipid peroxidation and heme oxygenase-1 activity were increased compared to the cortical regions [21] . The increased vulnerability of the olfactory epithelium in AD is suggested by a decreased number of ORN immunoreactive for calbindin-D28k, a calcium binding protein; although their number decreases with age as well, it was found significantly decreased in AD compared to age-matched controls [22] .
Pathology of the olfactory bulb (Figure 2)
Axons of the ORN branch in the most superficial layer of the OB, forming the olfactory nerve layer (ONL), followed by the glomerular layer (GLL), where olfactory glomeruli are found. The organization of this complex neuronal structure is damaged during the course of AD.
Olfactory nerve fibers enter the deeper parts of the OB (misrouted fibers) and form glomeruli outside the GLL (ectopic glomeruli), which can be hyperplastic [25] [26] [27] . Their biochemical character is distinct, as marked by the findings that, while in controls the greatest density of dopamine D2 receptors was found in the GLL of the bulb, in AD the labeling of the GLL was decreased so that glomerular and granular layers did not differ in labeling density [28] .
There is robust data [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] in literature about amyloid and neurofibrillary pathology of the OB in AD and aging.
AD-type pathology is an early feature of the OB and there are cases in which neurofibrillary pathology appears in the OB earlier than in the entorhinal cortex [44] , which is the earliest site of neurofibrillary degeneration according to the Braak staging [45] . However, some studies have found that neurofibrillary pathology appears in the OB parallel to the entorhinal cortex [38] , or only in Braak stage 2 [40] . These differences can be explained by the different sampling protocols; in our study [44] , the OB was sectioned in its whole width and every fifth section containing the AON was stained, in contrast to randomly selected sections only from parts of the OB.
In addition, Alzheimer-type pathology was detected in every AD patient in the majority of the studies [26, 37, [39] [40] [41] [42] [43] , and in varying degree of the age-matched control cases, ranging from all of the cases [26] to none of the cases in Braak stage 0 and 1 [40] .
Tau-immunoreactive fibers were found in the ONL, proving that the axons of the ORN are affected by neurofibrillary degeneration [26] . The majority of the NFT are located in the AON, although NFT-bearing neurons are found in every layer. Similarly, amyloid pathology was found in all AD cases. The distribution of senile plaques was different between control and AD cases: no classical (cored) and burnt-out plaques were detected in controls, while primitive plaques were more frequent in AD. The majority of senile plaques were of the diffuse type in both groups [26] , which are regarded to be less toxic for the neurons in contrast to cored and primitive plaques [46] .
In addition to tau and β-amyloid pathology, α-synuclein deposition and Lewy body pathology is common in the OB in AD [42, 47, 48] , especially in Lewy-body variant AD [48] . The OB was found to be equally vulnerable to tau and α-synuclein pathology as the amygdala, which suggests linked neurodegeneration in these two anatomically remote regions [42] .
There are data that show Alzheimer-type pathology is selective in the OB. For example, the number of somatostatin-containing neurons in the AON is reduced in AD and frequently shows co-localization with tau or β-amyloid [43] . Contrary to this parallel distribution, no correlation was found between cholinergic axons and AD-type pathology [37] . Recently, bipolar secretagogin-expressing neurons were described in the OT, which were selectively decreased in number in AD [49] . They expressed markers suggesting that their neuronal terminal differentiation is lacking [49] , which raises the possibility that regenerative processes are damaged in the olfactory system in AD.
The extensive pathology of the OB in AD is highlighted by Mundinano et al. [50] , who found that the volume of the OB was decreased only in patients with AD, while in PD and frontotemporal dementia it was similar to controls. In addition, the number of periglomerular dopaminergic cells was increased in AD and PD, which could reflect a compensatory mechanism created by the early degeneration of other neurotransmitter systems.
As a result of the extensive neuronal pathology both in the OB and in the olfactory cortical structures, the consequent axonal degeneration destroys the axons in the OT, which is manifested by loss of density and decreased cross-sectional areas of the OT [51, 52] .
These severe morphological alterations of the OB and OT described by histological methods were verified by imaging studies.
Using magnetic resonance (MR) volumetric measurements, Thomann et al. [53, 54] found that, compared to age-matched controls, the most severe atrophy of the OB and OT was seen in AD; but, atrophy was already found in mild cognitive impairment (MCI), suggesting early involvement of the olfactory system. The degree of atrophy correlated with the global cognitive performance as measured by the Mini Mental State Examination scores [54] .
Pathology of the cortical olfactory structures
Axons of the mitral cells project to the medial surface of the temporal lobe in the piriform, Atrophy of cortical olfactory areas was found by imaging methods, even in patients with MCI who later converted to AD; in these patients, volume loss in the olfactory and polysynaptic hippocampal network was significantly greater than in the MCI patients who did not convert to AD [57] . Atrophy of the medial temporal lobe structures correlated with an olfactory deficit [58] , and a decrease in olfactory cortical network clustering was a discriminative feature of AD [59] . Orbitofrontal cortical atrophy was detected even in incidental AD [60] .
Atrophy in AD was also found in the medial subnucleus of the amygdala receiving olfactory afferents [61] .
Olfactory dysfunction in AD
Olfaction is a composed function of olfactory threshold, odor identi cation and odor discrimination capabilities [2] . Olfactory threshold is the measure of the lowest concentration of an odorant which activates the olfactory receptor cells. Odor identification is the ability to identify and name odorants, while odor discrimination is the ability to differentiate between odorants. Olfactory threshold is likely to be influenced by the most peripheral part of the olfactory system, while discrimination and identification are partly cognitive tasks depending on central olfactory structures [62] .
Olfactory threshold performance is significantly influenced by sniffing ability [63] . In PD, sniffing is altered [64] , while in AD this deficit is not yet reported. [67] showing that anosmia was associated with Lewy bodies, rather than Alzheimer-type pathology in demented patients. Anosmia was found in 65% of patients with AD with concomitant Lewy-body pathology, while in pure AD it was found in only 23% [68] . It seems that olfactory identification ability is more severely damaged in dementia with Lewy bodies than in AD [69, 70] . However, these findings are likely influenced by the frequent co-localization of Alzheimer-type and Lewy-body pathologies [71] .
The effect of AD on olfactory function is complicated by the fact that impaired olfaction is an age-related process: the best odor performance is measured between 20 and 40 years of life, with steady decline after this age, which can result in complete anosmia in elderly people [72] . Similarly, during aging, Alzheimertype changes appear in the brain. We have shown that 86% of normal aged subjects have NFT in the OB [26] . In subjects with olfactory dysfunction without neurological symptoms, Lewy bodies [73] and Alzheimer-type pathology [74, 75] were detected in the brain. In addition to age-related changes of the olfactory epithelium [76, 77] and the loss of mitral cells in the OB [23] , these alterations might contribute to the age-related olfactory loss.
Despite the confounding effect of the loss of olfactory function with age, olfactory testing may be a useful tool in predicting cognitive decline in high-risk settings [78, 79] . Olfactory identification deficit was found to predict the development of MCI [80] , and subjective memory complaints were significantly associated with olfactory discrimination and identi cation de cits [81] . Olfactory deficit is present in MCI [82, 83] , independently from its subtype (amnestic or other) [84] .
Conversion of MCI to AD was predicted by olfactory identification deficit alone [75] or in combination with other early markers such as hippocampal volume on MR imaging and memory tests [85, 86] . The finding that MCI patients who were unaware of their deficit were more likely to convert to AD [87] was recently debated [88] . by fMRI in AD [92] . The activation of the primary olfactory cortex was decreased in AD patients on PET also [93] .
ApoE polymorphism was shown to influence olfactory functions in MCI and in AD. Carrying the ε4 allele causes more pronounced olfactory deficit in MCI [94] . In addition to predementia and dementia cases, it was shown that the ε4 allele is associated with odor identi cation deficit in elderly people (75-80 years), independent from dementia conversion within 5 years [95] . Only olfactory identification, but not threshold levels, was affected by the ApoE ε4 carrier status [96] . However, it should be mentioned that, because of the long preclinical stage of AD [97] , at least some of the ApoE ε4 carriers in these samples might have had AD-type pathology. This idea is supported by the findings of Handley at al. [98] , who found that ApoE ε4 positive siblings with family history of AD had significantly higher olfactory identification deficit than ApoE ε4 positive cases without it. Odor identification deficit was also shown in members of families who are genetically at risk for developing AD, independent of the ApoE status [99] .
Interestingly, in patients who were carrying the presenilin 1 (PSEN1) mutation, olfactory tests were normal ten years before the development of dementia [100] .
Olfactory dysfunction correlates to general cognitive functions [101] [102] [103] in AD and can be used to differentiate AD from major depression [104] . The differential diagnostic ability of olfactory dysfunction from other neurodegenerative disorders with dementia is poor because decreased olfaction is common among these disorders [2] ; however, the degree of involvement is more severe in AD compared to frontotemporal lobar degeneration syndromes (frontotemporal dementia, semantic dementia and corticobasal degeneration) [105] .
The role of the olfactory system in the pathogenesis of AD The olfactory connection in these disorders is highlighted by the fact that olfactory dysfunction is present in almost all cases in early, and even preclinical stages of AD and PD.
The olfactory connection has become a popular topic recently in regards to PD, where the spreading of an unknown pathological agent is suspected through the olfactory pathways, in addition to the earlier hypothesis where this spreading happened only through the vagus nerve from the gastrointestinal system (the so called "dual hit" hypothesis) [106] .
The olfactory vector hypothesis [107] [108] [109] suggests that environmental toxins, viruses, bacteria, or prions enter the central nervous system through the olfactory system, leading to pathological changes in the brain. However, the nature of these agents remains unknown, even after several propositions (reviewed by Honjo et al. [110] ) which were all later debated.
One of these agents is herpes simplex virus type 1 (HSV1); its role in the AD pathogenesis was recently reviewed by Speljko et al. [111] .
Acute infection of the brain by HSV1 causes herpes encephalitis, where the affected regions [112] are in close similarity with the most severely involved areas in AD belonging to limbic structures, such as the medial temporal and orbitofrontal areas. Olfactory dysfunction is present in patients who survive herpes encephalitis [113] . In the early studies of Mann et al. [114] , HSV1 antigens were detected in the olfactory tract. The idea of trans-olfactory spreading of HSV1 was proposed more than 30 years ago [115, 116] .
Among bacterial agents, the role of Chlamydia pneumoniae should be highlighted (see the review of Balin et al. [117] ).
C. pneumoniae is a ubiquitous organism and has been found in 90% of the brain samples of AD patients, in contrast to 5% positivity in non-AD cases [118] . Besides hematogenic spreading in macrophages, C. pneumoniae is known to attach to the nasal epithelial and olfactory neuroepithelial cells, and its genetic material was found in the OB, from which it can spread in the brain and induce pathology [117] .
In addition to infectious agents, toxic substances, such as trace elements including zinc, iron, and aluminum, were also postulated in the pathogenesis of AD and were found to have accumulated in the olfactory areas of the brain in AD [119, 120] .
It should be emphasized that there are several arguments against the olfactory vector hypothesis; some of them listed by Doty [108] , such as the existence of familiar forms of AD, the lack of olfactory dysfunction in some AD patients, and the more severe involvement of central olfactory structures than peripheral ones. A case report by Arriagada et al. [121] is also mentioned as an argument against this hypothesis: a 65-year-old patient is described with olfactory dysgenesis (the cribriform plate was imperforated and the olfactory bulbs were not developed) accompanied by NFT in the limbic cortex. However, it is curious that senile plaques were not found in the patient's brain, raising the possibility that this patient had a form of NFT pathology other than AD, such as frontotemporal degeneration.
The olfactory hypothesis was interpreted by Pearson et al. [122, 123] , in such a way that AD pathology begins in the olfactory centers of the medial temporal lobe and spreads in the retrograde direction via transneuronal pathways. However, this type of spreading was not found in our study [44] ; for example, the olfactory neocortex was affected less severely than the medial orbitofrontal cortex. This suggests that the olfactory orbitofrontal cortex, with close connections to the primary olfactory cortex in the medial temporal lobe, was affected in later stages of AD than the medial orbitofrontal cortex, which is part of the limbic system and has no olfactory input. We found 
Olfactory system as a therapeutic pathway in AD
Intranasal delivery of treatment is a feasible option in CNS diseases; it may decrease or abolish the side-effects seen after systemic administration and can substitute invasive methods of substance delivery.
Although recent results with amyloid vaccination in general are disappointing [125] , nasal vaccination with β-amyloid for the treatment of AD was suggested [126] . It has been shown that β-amyloid peptide in rats is transported to the OB and frontal cortex after intranasal delivery [127] .
Cholinesterase inhibitors are used to ameliorate the cholinergic hypofunction in AD [128] . The synaptic integrity and cholinergic phenotype of basal forebrain neurons is maintained by a neurotrophic factor, nerve growth factor (NGF) [129, 130] . There were promising trials using intracerebral NGF delivery for the treatment of AD [131] [132] [133] with limitations because of invasive methods of delivery. Intranasal NGF delivery, on the other hand, is an easy way of application, and it was found to be effective in animal experiments [129, 134] , even with higher bioavailability than after ocular administration [135] .
The advantage of intranasal delivery of insulin compared to systemic administration is obvious. It is widely established that insulin has a substantial effect on synaptic functions of brain neurons [136] and facilitates memory formation [137] . In AD, insulin levels and insulin activity is decreased [138] . Because of this, AD is even mentioned as type 3 diabetes [139] .
Owing to these features, one can hypothesize that normalization of brain insulin levels might improve the symptoms of AD. However, systemic administration of insulin in AD is problematic because the risk of hypoglycemia.
Intranasally administered insulin avoids this
unwanted systemic response and has no major side-effect [140, 141] . Initially, the effect of intranasal insulin on memory functions in AD and in MCI in acute conditions (after 15 minutes of application) were studied and found to be improved depending on the ApoE ε4 status; only patients negative for apoE ε4
improved in verbal memory domains [142] .
Verbal memory (together with attention and caregiver-related functional status) of AD patients also improved after 21 days of intranasal insulin treatment using 20 IU BID.
Plasma levels of the shorter form of amyloid β (40 amino acid) were reduced without affecting the levels of the longer (42 amino acid) isoform [143] . Based on these results, a study with a longer treatment period was published recently [144] . These results suggest that studies with longer treatment duration are necessary.
Because vitamin D regulates insulin receptor expression and enhances insulin action [145, 146] , a randomized controlled trial was performed with high-dose vitamin D2 treatment, followed by intranasal insulin application in AD patients [147] . The study did not find an effect of high-dose vitamin D2
treatment, but intranasal insulin was effective on the ADAS-Cog (Alzheimer's Disease Assessment Scale-cognitive subscale) scale [147] .
In case of cholinesterase inhibitors, systemic side-effects are also limiting their use. Tacrine, the rst cholinesterase inhibitor developed to treat AD, was found be transported into the brain from the nasal cavity. Intranasal administration resulted in higher bioavailability and reduced distribution into non-targeted organs in animal experiments [148, 149] , creating a possibility to decrease its systemic side-effects, which might be an option for other cholinesterase inhibitors too.
Besides providing a therapeutic pathway, olfactory system and olfactory function testing can also be used as a treatment response marker in AD. Keeping in mind that the OB and the cortical olfactory areas are rich in cholinergic innervation [150, 151] , the effect of cholinesterase inhibitors might be measured through the changes seen in olfactory tests.
Velayudhan and Lovestone [152] found that after a three month treatment with the cholinesterase inhibitor donepezil, the change in smell identification function was the best predictor of the change seen in the Clinician
Interview Based Impression of Change plus caregiver input (CIBIC-plus) scale.
Besides cognitive symptoms, behavioral and psychological symptoms of dementia (BPSD) are frequent in AD, and are especially important regarding caregiver stress. Aromatherapy could be one of the alternative therapeutic methods to control agitation in AD, but a study using Melissa officinalis oil found that aromatherapy was not superior to placebo or donepezil in the treatment of agitation in AD [153] .
Conclusion
Olfactory system pathology is well described 
